24 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
of the trial is progression-free survival (PFS) by RECIST 1.1 per blinded independent central review (BICR) for Arm A vs. Arm C. Secondary endpoints include
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
of overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR). With a median follow up
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
Independent
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
ABBV
ATNM
AZN
19 Apr 24
is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor
77re4on97y4oascijyp9z5txzk2i3kqatm0w9w64yo
ATNM
AZN
BMY
17 Apr 24
broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment
d6572g lwgreb68aeacayu2rtuy
BMY
6 Apr 24
, people living with schizophrenia often struggle to maintain employment, live independently, and manage relationships. While current treatments can
ry0t86hyvanz6g 34jrctytano4vsy3k
BMY
IRON
VERV
4 Apr 24
demonstrated superior efficacy compared to epoetin alfa in the study's primary endpoint of concurrent red blood cell transfusion independence and hemoglobin
wlhewxkl3gf6z
BMY
3 Apr 24
the percentage of patients achieving transfusion independence and hemoglobin increase, along with increased durability compared to epoetin alfa
6sq2v1c5yu1h5j7o4pvr058r9fje 5siro4fb6qa132om
BMY
2 Apr 24
study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence
mrc2fh4r41eqwbku2e6we7dwv3yh5hseugd61h2ic7phv3qequxidm13
ARGX
ATNM
AZN
22 Mar 24
zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent
ns7flap5j2iwv f0u0pj4h1xaysy0xvqwtzl4f127xqt9r
ABBV
ANIX
BIIB
20 Mar 24
. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
nom ew592xzw7k
BMY
GERN
15 Mar 24
.
The primary endpoint of red blood cell transfusion independence (RBC-TI) for at least eight consecutive weeks was significantly higher with imetelstat vs
bqy742fdil30a1jbmp9kp9i43hehl9buay53l192
BMY
14 Mar 24
of the Phase 2 portion of the study is complete response rate, including complete remission with incomplete bone marrow recovery, based on independent
fuyockov4kw4rvyau3y14a54c7pksa9w4xmtnmadwcgj
BMY
7 Mar 24
overall survival (OS) and progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR